|Year : 2023 | Volume
| Issue : 1 | Page : 16
Detection of colistin resistance via four methods among Gram-negative bacteria
Praveen Kumar Gautam, Shama Tomar
Department of Microbiology, National Institute of Medical Sciences & Research, Jaipur, India
|Date of Submission||16-Apr-2023|
|Date of Decision||31-Jul-2023|
|Date of Acceptance||06-Aug-2023|
|Date of Web Publication||18-Sep-2023|
Praveen Kumar Gautam
Department of Microbiology, National Institute of Medical Sciences & Research, Jaipur
Source of Support: None, Conflict of Interest: None
Objective: We aimed to find the most accurate and robust method for the detection of colistin resistance among Gram-negative bacteria by comparing the performance of four methods.
Methods: Colistin resistantance was determine by disk diffusion (DD), Etest, colistin broth disk elution (CBDE) and compared with standard broth microdilution (BMD) method.
Results: An exploratory study was conducted in a tertiary hospital in Jaipur, India, from November 2021 to November 2022. Of the 384 isolates tested, 41 (10.7%) were resistant against colistin by BMD and CBDE testing. Compared with BMD method, the categorical agreement of DD and Etest methods were 65.9% and 78.1%, respectively, and the rates of very major error were 34.1% and 21.9%, respectively.
Conclusions: Due to the high frequency of very major error, the use of DD and Etest are not recommended by Clinical laboratory and standards institute (CLSI) for colistin susceptibility testing while CBDE is the recommended method which yields a categorical agreement of 100% with BMD method. The CBDE method can be used in routine laboratories for the detection of colistin resistance.
Keywords: Disk diffusion; Etest; Broth micro dilution method; Colistin broth disk elution; Colistin
|How to cite this article:|
Gautam PK, Tomar S. Detection of colistin resistance via four methods among Gram-negative bacteria. One Health Bull 2023;3:16
|How to cite this URL:|
Gautam PK, Tomar S. Detection of colistin resistance via four methods among Gram-negative bacteria. One Health Bull [serial online] 2023 [cited 2023 Sep 28];3:16. Available from: http://www.johb.info/text.asp?2023/3/1/16/385536
| 1. Introduction|| |
Approximately 700 000 deaths in world are attributed to antimicrobial resistance. This number is supposed to increase to ten million by the year 2050, by mortality attributed to antimicrobial resistance overhanging to outrun worldwide general causes of death. One key technique for preventing antimicrobial resistance is the elimination of commonly used antibiotics. In this circumstances, use of an old forgotten antibiotic colistin has been increasing in the recent past.
Colistin is a cationic polypeptide antibiotic of the polymyxin family that is rapidly bactericidal to Gram-negative bacteria and is generated spontaneously by Bacillus polymyxa.
Bacterial death is caused by interference with the structure and function of the outer cell membranes. Colistin was initially launched in 1952 and was used to treat Gram-negative bacilli infections till the early 1980s. Its systemic usage was halted due to adverse issues such as nephrotoxicity, neuromuscular inhibition, and neurotoxicity,.
Despite the fact that colistin has been utilised in clinical sectors for a long time, the appropriate susceptibility testing methods for colistin remained unknown until recently. The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) combined taskforce both approved broth microdilution (BMD) as the reference technique in 2015.
| 2. Materials and methods|| |
2.1. Study area
This was a one-year hospital-based study conducted at the department of Microbiology, National Institute of Medical Sciences, Jaipur, India, from November 2021 to November 2022.
2.2. Sample processing
Specimens of urine, pus, blood, endotracheal-tube, sputum, swab and fluids obtained from patients were cultured on routine bacteriological media. Biochemical identification and antimicrobial susceptibility testing of the isolates were performed according to the standard laboratory procedure. Gram-negative bateria isolated showing resistance by disk diffusion (DD) method were further analysed by Etest, Colistin broth disk elution method (CBDE) and confirmed by BMD method.
2.2.1. Identification of bacterial isolates
After inoculation on solid media i.e MacConkey agar and Blood agar (HiMedia Laboratory Pvt. Ltd), all plates were incubated at 37 °C temperature for 18-20 hours. The next morning, gram staining was performed for morphology identification and standard biochemical test was done for species identification.
2.2.2. Screening by disk diffusion method
The colistin disk difussion test was performed using a 10 µg colistin disk (HiMedia Laboratory Pvt. Ltd) onto the surface of muller-Hinton agar (HiMedia Laboratory Pvt. Ltd) plate that were incubated at 37 °C for 18-24 hours. As the antibiotic diffused from the filter paper disk into the agar surface, it inhibited the bacterial growth around the disk. The effectiveness of the antibiotic can be calculated by measuring the size of the zone of inhibition.
The minimum inhibitory concentration (MIC) was determined by using E-strip method. An E-strip containing different concentration of colistin was placed onto the surface of Muller-Hinton agar plate. As colistin diffused onto the surface of agar, it inhibited the bacterial growth. The lowest concentration of colistin that will inhibit the visible growth of bacteria is defined as MIC. Isolates with MIC ≤ 2 mg/L were considered sensitive, while isolates with MIC ≥4 mg/L were considered resistant.
2.2.4. Colistin broth disk elution method (In house modification)
CBDE was performed with four, 10 ml cation-adjusted Mueller Hinton broth tubes per isolate, to which 0, 1, 2, and 4 colistin 10 µg disks were added, generating a final concentration of 0 (growth control), 1, 2 and 4 µg/mL in the tubes. All tubes were incubated at 37 °C for 30-45 minutes to elute the colistin from the disks. Prepare the inoculum by suspending pure colonies from blood agar in normal saline and adjusting the turbidity to match 0.5 MaFarland turbidity. MIC values were read after 18-24 hours of incubation at 37 °C. The result of colistin MIC were interpreted as per CLSI-2022.
2.2.5. Broth microdilution method
BMD was performed in accordance with CLSI recommendations. Colistin sulphate powder (19 000 U/mg) was bought from HIMEDIA Pvt. Ltd, Mumbai, India with two-fold drug dilutions in range of 0.125 to 16 µg/ml were prepared in autoclaved distilled water. The cation-adjusted Mueller Hinton Broth (CAMHB) was prepared according to the manufacturer’s instructions. A bacterial suspension with a concentration of 5 x 105 CFU/ml was prepared and inoculated in a micro-titre plate. Growth and sterility controls were placed in the last two wells of each micro-titre plate row. Bacterial suspension was the sole substance in the growth control well, while CAMHB was the only substance in the sterility control well.
Finally, the micro-titre plates were then incubated for 16-18 hours at 37 °C in incubator. The MIC of colistin was determined as the lowest concentration that inhibited observable bacterial growth. The results were interpreted in accordance with CLSI-2022.
| 3. Results|| |
The study was conducted in the Department of Microbiology from November 2021 to November 2022. A total of 384 samples were received in microbiology samples including urine 173 (45.1%), pus 88 (22.9%), blood 58 (15.1%), endotracheal aspirates 39 (10.2%), and sputum 26 (6.8%).
Out of 384 Gram-negative clinical isolates, the predominant Gram-negative bacteria was Escherichia coli (145, 37.8%), followed by Klebsiella pneumoniae (131, 34.1%), Pseudomonas aeruginosa (65, 16.9%), Acinetobacter baumannii (31, 8.1%), Enterobacter cloacae (8, 2.1%) and Citrobacter frundii (4, 1.0%) [Figure 1].
Among 384 clinical samples, maximum organism was isolated from intensive care unit (ICU) (154, 40.1%), followed by medicine (74, 19.3%), surgery (37, 9.6%), obstetrics & gynecology (31, 8.1%), pediatrics (22, 5.7%), orthopedic (21, 5.5%), nephrology (14, 3.6%), oncology (12, 3.1%), urology (10, 2.6%) and gastrology (8, 2.1%).
All the clinical isolates were tested for colistin resistance by four phenotypic test. The DD method detected 7.0% (27/384), by Etest 8.3% (32/384) and by CBDE 10.7% (41/384). All resistant isolates were subjected to confirm resistance by BMD (Gold standard method) and MICs were noticed [Table 1].
|Table 1: Detection of colistin resistance organism by DD, Etest, CBDE and BMD.|
Click here to view
Out of 384 isolates, 148 isolates showed colistin MIC of ≤0.5 µg/mL, 134 isolates had MIC of 1 µg/mL, 61 isolates had MIC of 2 µg/mL, 24 isolates had MIC of 4 µg/mL, 6 isolates had MIC of 8 µg/mL, and 11 isolated had MIC of 16 µg/mL. The MICs of all Gram-negative clinical isolates are shown in [Table 2].
|Table 2: Distribution of MICs of colistin for all clinical isolates (n=384).|
Click here to view
Of all the colistin resistant isolates, the majority were from ICU (13, 31.7%), followed by medicine (9, 22.0%), orthopaedic (4, 9.8%), pediatrics (3, 7.3%), surgery (3, 7.3%), gastrology (3, 7.3%), urology (2, 4.9%), nephrology (2, 4.9%), and obstetrics & gynecology (1, 2.4%), oncology (1, 2.4%), respectively. The maximum colistin resistant isolates were from urine (20, 48.8%), followed by pus (14, 34.1%), blood (4, 9.8%), endotracheal aspirates (2, 4.9%), and sputum (1, 2.4%), respectively.
The CBDE method showed 100% concordant results for all colistin resistance clinical isolates. The performance of CBDE, Etest and DD methods compared to the BMD method were evaluated on the parameters of major error, very major error, categorical agreement, sensitivity, specificity, positive predictive valves and negative predictive value. The very major error was 34.1% for DD test while no major error was seen for CBDE method.
Categorical agreements of colistin disk elution method was 100%, while for Etest method and DD methods was 78.1% and 65.9% respectively when compared with BMD method.
Compared with BMD, the sensitivity of CBDE method, Etest, and DD method was 100%, 78.1%, and 65.9%, respectively. The specificity and positive predictive value of all phenotypic tests was 100% while negative predictive value of colistin broth elution method, Etest, and DD method was 100%, 97.5%, and 96.2%, respectively [Table 3].
|Table 3: Performance of CBDE, Etest and DD when compared with BMD (n=384).|
Click here to view
| 4. Discussion|| |
Colistin should be kept and used sparingly after antibiotic susceptibility testing and antibiotic stewardship as the last resort medication dut to lack of development of new antibiotics for the treatment of drug-resistant Gram-negative strains.
The emergence of multi-drug resistant Gram-negative isolates in clinical settings, as well as difficulties in colistin susceptibility testing, have resulted in a disastrous situation in treating severe infections. Colistin susceptibility testing is hampered by some issues, such as a lack of agreement on drug resistance breakpoints.
The prevalence of colistin resistant Gram-negative clinical isolates found in this study was 10.7%. Similarly, another study has reported less than 10% colistin resistant globally whereas the quite higher prevalence in India and Philippines with 13.8% and 50% respectively. This variation may be the result of geographic variation, the difference study population, and variation in colistin use.
The distribution of colistin resistance Gram-negative isolates within hospital wards present a shocking picture as most of the colistin isolates were from the ICU, and various studies all around the worlds supports these findings. The use of colistin to treat patients, various surgical procedures, and extended stays in the ICU may all contribute to emergencies,,. The high incidence of these isolates in the ICU and other wards possess a great challenge for their treatment.
The evaluation of colistin resistance is very significant for infection control. In this context, the goal of this study was to assess colistin resistance among Gram-negative clinical isolates using DD, Etest and CBDE, then compared them with BMD which is reference method for colistin susceptibility testing.
The DD method of antimicrobial susceptibility testing has been rather unpopular for colistin. In this study, DD for colistin carried out using Piewngam’s criteria.
The categorical agreement of DD with BMD was 65.9% in present study with very major of 34.1%. Studies done by various authors’ show the categorical agreement ranging from 88.7%-91.2%,,.
In the present study, the categorical agreement of Etest found to be 78.1% with very major error of 21.9%. This colistin MIC by Etest was supported by other studies,,.
The categorical agreement of CBDE with BMD was 100% with no very major error. The very major error greater than 3% indicates that DD and Etest are not reliable methods for testing colistin susceptibility and thus could not meet the CLSI recommendation as an alternative method for reference BMD testing. CBDE could be used as an alternative method for routine laboratory colistin susceptibility testing as it is simple, reliable, and cost effective while BMD require high expertise, and training.
| 5. Conclusions|| |
As the burden of adaptive resistance to colistin grows, it is critical to develop a diagnostic stewardship programme, particularly for countries such as India. The current investigation revealed a high prevalence of colistin resistance among drug resistant individuals suffering from various illnesses. This demonstrates the critical need of rewarming antibiotic-treatment techniques for people. Routine testing of colistin MIC should be done by CBDE method to prevent the increasing use of colistin to treat drug resistant bacterial infections. CBDE method is easy to used and as sensitive as broth micro dilution method.
Conflict of interest statement
The authors declare that there is no conflict of interest.
We would like to thank NIMS University for providing facilities.
The authors received no extramural funding for the study.
Gautam PK and Tomar S conceptualized the study: PK Gautam curated the data: S. Tomar carried out supervision of study
| References|| |
Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother
Yow EM, Tan E, Shane L, Schonfeld S, Abu-Nassar Hanna. Colistin (colymycin) in resistant bacterial infections. A clinical appraisal. Arch Intern Med
Bialvaei AZ, Kafil SH. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin
Trebosc V, Gartenmann S, Tötzl M, Lucchini V, Schellhorn B, Pieren M, et al. Dissecting colistin resistance mechanisms in extensively drug-resistant acinetobacter baumannii clinical isolates. mBio
Janssen AB, van Hout D, Bonten MJM, Willems RJL, van Schaik W. Microevolution of acquired colistin resistance in Enterobacteriaceae from ICU patients receiving selective decontamination of the digestive tract. J Antimicrob Chemother
Panigrahi K, Pathi BK, Poddar N, Sabat S, Pradhan S, Pattnaik D, et al. Colistin resistance among multi-drug resistant gram-negative bacterial isolates from different clinical samples of ICU patients: Prevalence and clinical outcomes. Cureus
Piewngam P, Kiratisin P. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii
clinical isolates, including multidrug-resistant isolates. Int J Antimicrob Agents
van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant Pseudomonas aeruginosa
to polymyxins. Ann Clin Microbiol Antimicrob
: 8. doi: 10.1186/1476-0711-6-8.
Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, et al. Evaluation of susceptibility testing methods for polymyxin. Int J Infect Dis
Gupta P, Sharma R, Vyas A, Tak A. Comparative evaluation of broth micro dilution with E-test, Vitek 2, and disk diffusion for susceptibility testing of colistin on Gram-negative bacteria. Indian J Med Sci
Publisher’ s note
The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
[Table 1], [Table 2], [Table 3]